EXECUTIVE INTERVIEW – Patheon: Comprehensive Development & Manufacturing Solutions for the Entire Drug Development Cycle
Franco Negron, Patheon’s Senior VP of Drug Product Services, discusses his company’s business strategy, two recent acquisitions and integration plans, the role biosimilars play in Patheon’s business, and significant trends driving the pharmaceutical industry over the next few years.
EXECUTIVE INTERVIEW – SOLIZE: 3D Data-Based Engineering & Manufacturing to Accelerate Delivery Device Development
Yoshiki Matsuda, Director of SOLIZE, discusses how his company can create new and innovative solutions to accelerate the development of devices and combination products built thereon.
Niels Düring discusses Gerresheimer’s Plastic Packaging division and the complementary synergies working for a company that also manufactures glass provides.
EXECUTIVE INTERVIEW – Croda: Understanding & Addressing the Purity Needs of the Pharmaceutical Market
Dr. Andrew Kaziska, Health Care Applications Manager at Croda Inc, discusses his company’s Super Refining technology and the benefits of excipient purity in drug formulations.
Jingjun (Jim) Huang, PhD, CEO, and Founder of Ascendia, discusses his company’s unique vision and strategy to provide pharmaceutical companies with a contract research partner that can provide technologies in order to efficiently determine which approach is most suitable for a given molecule.
Shri Thanedar, PhD, CEO & Chief Chemist at Avomeen Analytical Services, discusses what sets his company’s analytical laboratory apart from other CROs that serve the pharmaceutical industry.
EXECUTIVE INTERVIEW – Exostar: Speeding the Drug Development & Delivery Process Through Secure Communities of Industry Partners
Drug Development Executive: Tom Johnson, Exostar’s Senior Director of Pharma and Life Science Solutions, discusses how Exostar’s Life Sciences Identity Hub efficiently and cost effectively brings organizations, individuals, applications, and information together to promote the external collaboration initiatives imperative to today’s drug research and development processes.
Drug Development Executive: Mark Rogers, PhD, Senior Vice President Life Science Services at SGS, talks about his company’s evolutionary development and the trends it is witnessing in the analytical testing market.
Drug Development Executive: Richard Mutchler, President of BioSpectra, discusses the company’s unique ability to provide customers with validated, secure, and traceable intermediates that remain affordable.
Drug Development Executive: Guillermo DiClemente, Founder & President of Cronos Clinical Consulting Service, discusses the company’s unique approach, its relationship with customers, industry trends, and the importance of focusing on quality clinical data.
EXCLUSIVE ONLINE CONTENT
Thermo Fisher Scientific Inc. recently announced its intent to open multiple Global Customer Solution Centers. The new Global Customer Solution Centers will focus on meeting and exceeding the demands of scientists in food, beverage, pharmaceutical and biotech laboratories by developing critical workflows and integrated solutions that help advance chromatography and mass spectrometry worldwide.